Inactive

The United States Army Medical Research Acquisition Activity (USAMRAA) has a new requirement in support of the U. S. Army Research Institute of Environmental Medicine (USARIEM) for Urine Biochemistry ... The United States Army Medical Research Acquisition Activity (USAMRAA) has a new requirement in support of the U. S. Army Research Institute of Environmental Medicine (USARIEM) for Urine Biochemistry Analysis Services. The required services will be located at the contractor’s location. This requirement will be a full and open competitive solicitation under the North American Industry Classification Code of 541715 with a size standard of 1000. USAMRAA intends to award a firm fixed price contract to include one twelve (12) month base period and 1 twelve (12) month option period at Ft. Detrick, MD. The closing date for receipt of proposals is on or about 05 December at 10:00AM ET The solicitation will be posted on or about 05 November 2020 at www.beta.sam.gov. No solicitations will be accepted by hard copy. All offerors are responsible for checking for amendments to the solicitation from the Internet. It is the responsibility of the vendor to ensure that the RFQ is received from the Internet accurately and in its entirety. To be eligible for an award or payment from any DOD activity, offerors must be registered with the System for Award Management at https://www.sam.gov/SAM/ and have completed the on-line representations and certifications located at https//www.sam.gov/SAM/. Any questions concerning this notice must be submitted to Flodean.p.billings.civ@mail.mil

Inactive

Title: Urine Biochemistry Analysis Services U. S. Army Research Institute of Environmental Medicine Solicitation: PANMRA-20-P-0000-004821 Notice Type: Request for Information (RFI) Response Date: 08 O... Title: Urine Biochemistry Analysis Services U. S. Army Research Institute of Environmental Medicine Solicitation: PANMRA-20-P-0000-004821 Notice Type: Request for Information (RFI) Response Date: 08 October 2020 NAICS: 541715 – Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) Scope: Urine samples will be collected on 120 women daily throughout BCT. Urine samples will be aliquoted, frozen and transported to the contractor’s lab for batched analysis of, reproductive hormone metabolite (pregnanediol glucuronide (PdG;progesterone)), esterone conjugate (E1c;estradiol), follicle stimulating hormone (FSH) and leutinizing hormone (LH) Additionally, Contractor personnel designated shall have expertise as an accredited laboratory lead by a senior scientist with a terminal degree related to clinical chemistry. Contractor shall provide help desk/e-mail and telephone support to respond to USARIEM’s questions regarding data analysis. The Laboratory shall possess the specialized experience to provide the required measurement and analysis of biochemistries in human urine at this level of competency. In order to maintain consistency of methods from prior studies to the current planned studies, to ensure reproducibility and validity of conclusion derived from these studies, and to collate these data into meta-analyses, the analyses shall be performed exactly as listed above. Good Clinical Practices guidelines shall be followed in the laboratory, and the vendor’s laboratory systems shall be governed by a set of Standard Operating Procedures (SOP) that are annually reviewed and updated. All laboratory technicians assigned to perform procedures in the laboratory shall be trained on SOPs for specific methods and all instruments are evaluated for sensitivity, reproducibility and proper run conditions prior to sample analysis as well as completed appropriate lab safety and CITI training for working with human subjects’ samples. Each analytical run shall include a series of standards and controls to monitor the performance of the analytical instrument and to minimize any drift that may occur during the course of the run. The lead investigator in the lab must have recognized expertise in biochemical analysis and a terminal degree related in biochemistry, chemistry, biology or related field. The contractor shall accomplish the assigned tasks by employing and utilizing qualified personnel with appropriate combinations of education, training, and experience. The contractor shall match personnel skills to the task with a minimum of under or over employment of resources. (See attached DRAFT Performance Workstatement RFI INSTRUCTIONS: Interested parties are asked to respond to this RFI and submit a capabilities statement that supports the focus of this RFI. Please review the place of performance requirements. Please submit written responses via email in Microsoft Office 2000 or 2007 format. All responses should be complete: in 12-point font; and not to exceed 5 pages total, including graphics, tables, and appendices. No hardcopies shall be accepted. No written solicitation document is available at this time. Telephone requests will not be honored, and no bidders list shall be maintained. No inquiries regarding any potential future acquisition activities shall be entertained. There is proprietary information involved in this requirement which may preclude some established clinical trial centers from competing on this requirement, although no decisions have been finalized at this time. Potential offerors are requested to direct all questions via email to the Point of Contact listed below. Responses are due to the Point of Contact, Ms. Flodean Billings at email: flodean.p.billings.civ@mail.mil no later than 10:00AM ET, Thursday, October 8, 2020. CAUTION: This is an active requirement. Contractors are strictly prohibited from discussing this requirement with any member of the program office. All discussion shall be with the point of contact listed above. DISCLAIMER: This RFI is issued solely for information and planning purposes and does not constitute a solicitation. Neither unsolicited proposals nor any kinds of offers will be considered in response to this RFI. Responses to this notice are not offers and will not be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. All information received in response to this RFI that is marked proprietary will be handled accordingly. Responses to the RFI will not be returned.